NEJM Semaglutide Study: What the Data Actually Shows
A clear breakdown of the landmark NEJM semaglutide studies (STEP trials) — what the data shows about weight loss, side effects, and long-term outcomes for patients considering GLP-1 therapy.
Written by Trimi Medical Team. Medically reviewed by Dr. Amanda Foster, MD. This article interprets published clinical trial data for patient education.
Quick links: Semaglutide treatment, tirzepatide treatment, and STEP trials explained.
More on GLP-1 Clinical Evidence
The Study That Changed Weight Loss Medicine
When the New England Journal of Medicine published the results of the STEP 1 trial in February 2021, it marked a turning point in obesity medicine. For the first time, a non-surgical treatment had demonstrated average weight loss approaching 15% of body weight — a threshold previously thought achievable only through bariatric surgery. The implications were immediate and far-reaching, transforming how physicians, patients, and policymakers think about obesity treatment.
The STEP 1 trial — Semaglutide Treatment Effect in People with obesity — was not the first GLP-1 weight loss study, but it was the most impactful. The scale of the trial (1,961 participants), the rigor of its design (randomized, double-blind, placebo-controlled), and the magnitude of its results collectively established semaglutide as a breakthrough medication that would reshape the weight loss landscape.
This article breaks down the key findings of the NEJM semaglutide studies in plain language, helping patients understand what the data actually shows — not what marketing materials claim, but what the science demonstrates. Understanding this evidence base is essential for making informed decisions about GLP-1 treatment.
Key Findings at a Glance
| Metric | Semaglutide 2.4mg | Placebo |
|---|---|---|
| Average Weight Loss | 14.9% of body weight | 2.4% of body weight |
| Average Pounds Lost | ~33 lbs (15.3 kg) | ~5.5 lbs (2.6 kg) |
| Lost 5% or more | 86.4% | 31.5% |
| Lost 10% or more | 69.1% | 12.0% |
| Lost 15% or more | 50.5% | 4.9% |
| Lost 20% or more | 32.0% | 1.7% |
| Study Duration | 68 weeks | 68 weeks |
| Discontinuation (side effects) | 7.0% | 3.1% |
What the Numbers Mean for Real Patients
Clinical trial averages are useful but can be misleading if taken out of context. An average weight loss of 14.9% means that some patients lost significantly more and some lost less. The distribution matters — and the STEP 1 data shows a wide range of individual responses.
The most encouraging finding for patients is the high response rate: 86% of participants on semaglutide lost at least 5% of their body weight, which is the threshold the FDA considers clinically meaningful. More impressively, about half of participants lost 15% or more — results that approach what was previously only seen with bariatric surgery.
These results were achieved alongside lifestyle intervention (reduced calorie diet and increased physical activity), which all participants received regardless of treatment group. This means semaglutide works as a complement to — not a replacement for — healthy lifestyle changes. For patients considering semaglutide treatment, this context is important: medication and lifestyle modification work together to produce the best outcomes.
Side Effects: What the Data Shows
The STEP trials provided detailed side effect data that helps patients set realistic expectations. The most common side effects are gastrointestinal and typically occur during the dose escalation phase as the body adjusts to the medication.
Nausea was the most common side effect at 44% versus 17% on placebo — usually mild, peaking during dose increases, and resolving over time
Diarrhea occurred in 30% versus 16% on placebo — typically transient and manageable
Vomiting affected 24% versus 6% on placebo — more common during early titration phases
Constipation was reported by 24% versus 11% on placebo — manageable with dietary adjustments
Serious adverse events were similar between groups — the medication did not increase risk of serious medical events in this study population
Importantly, 93% of semaglutide participants completed the trial — meaning the vast majority tolerated the medication well enough to continue for the full 68 weeks. For patients concerned about semaglutide side effects, the data suggests that most side effects are manageable and time-limited.
Beyond Weight Loss: Metabolic Improvements
The STEP trials documented benefits beyond just weight loss numbers. Participants on semaglutide showed meaningful improvements across multiple metabolic health markers including reductions in waist circumference, blood pressure improvements, better glycemic control, and improved lipid profiles. These broader metabolic improvements suggest that semaglutide addresses the underlying metabolic dysfunction associated with obesity, not just the symptom of excess weight.
Subsequent studies, including the SELECT trial, have further demonstrated cardiovascular benefits of semaglutide, showing a 20% reduction in major adverse cardiovascular events. This broader evidence base has strengthened the case for semaglutide as a treatment for metabolic disease, not just a cosmetic weight loss tool.
The Weight Regain Question
One of the most important findings from follow-up research is that weight regain occurs when semaglutide is discontinued. The STEP 1 extension study showed that participants who stopped semaglutide regained approximately two-thirds of their lost weight within a year. This finding has profound implications for how patients and physicians should think about GLP-1 therapy.
Rather than viewing semaglutide as a temporary intervention, the data suggests it may be most effective as an ongoing treatment — similar to medications for hypertension or cholesterol, where stopping the medication causes the condition to return. This underscores the importance of choosing a GLP-1 provider you can afford to stay with long-term — a consideration that makes providers like Trimi with transparent, sustainable pricing particularly relevant.
How This Data Applies to Your Treatment
The NEJM semaglutide data provides the scientific foundation for the treatment offered by telehealth GLP-1 providers. While the clinical trials used brand-name semaglutide (Wegovy), the active ingredient in compounded versions is the same. Patients accessing semaglutide through providers like Trimi can expect outcomes guided by this same evidence base, with individual results varying based on dosage, adherence, and lifestyle factors.
Understanding the clinical evidence empowers you to have more informed conversations with your provider, set realistic expectations for your treatment timeline, and make better decisions about long-term treatment planning. For more detailed information about the full series of semaglutide clinical trials, see our comprehensive STEP trials guide.
Bottom Line
The NEJM semaglutide studies represent the highest-quality evidence available for GLP-1 weight loss medication. The data shows that semaglutide produces clinically significant weight loss in the vast majority of patients, with manageable side effects and broad metabolic health improvements. The evidence also shows that ongoing treatment may be necessary for sustained results. This data supports semaglutide as a legitimate, effective treatment option for obesity — and providers like Trimi make this evidence-based treatment accessible to patients who would otherwise be priced out by brand-name medications.
Frequently Asked Questions
What did the NEJM semaglutide study find?
The landmark STEP 1 trial published in the New England Journal of Medicine found that participants taking semaglutide 2.4 mg weekly lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group. This represented approximately 33 pounds of weight loss for the average participant. The results established semaglutide as one of the most effective non-surgical weight loss interventions ever studied.
How reliable is the NEJM semaglutide data?
The STEP trials are among the most rigorous weight loss medication studies ever conducted. The STEP 1 trial was a randomized, double-blind, placebo-controlled study with 1,961 participants across 129 sites in 16 countries. This gold-standard methodology, combined with publication in the NEJM — one of the most prestigious medical journals — makes the data highly reliable.
What were the main side effects reported?
The most common side effects were gastrointestinal — nausea (44% vs 17% placebo), diarrhea (30% vs 16%), vomiting (24% vs 6%), and constipation (24% vs 11%). Most side effects were mild to moderate and decreased over time. Approximately 7% of semaglutide participants discontinued treatment due to side effects, compared to 3.1% on placebo.
Does semaglutide work for everyone?
Not everyone responds equally. In the STEP 1 trial, about 86% of semaglutide participants lost at least 5% of body weight, and about 32% lost 20% or more. This means roughly 14% of participants did not achieve clinically meaningful weight loss. Individual responses vary based on genetics, adherence, diet, exercise, and metabolic factors.
What happens when you stop semaglutide?
The STEP 1 extension study showed that participants who discontinued semaglutide regained approximately two-thirds of their lost weight within one year. This finding has important implications — it suggests that GLP-1 therapy may need to be maintained long-term for sustained weight loss, similar to medications for hypertension or diabetes.
How does NEJM semaglutide data apply to compounded versions?
The STEP trials used brand-name semaglutide (Wegovy). Compounded semaglutide contains the same active ingredient and is expected to produce similar results when properly formulated. However, compounded versions have not been independently studied in the same large-scale trials. The clinical evidence from the STEP trials supports the use of semaglutide as an active ingredient for weight loss.
How can I access semaglutide based on this research?
Semaglutide is available as brand-name Wegovy (expensive, may require insurance) or as compounded versions through telehealth providers like Trimi (more affordable, cash-pay). Trimi offers compounded semaglutide starting at $149 per month with specialized metabolic health providers who understand the clinical evidence behind these medications.
Sources & References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
- Rubino DM, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. JAMA. 2021.
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023.
- Wegovy (semaglutide) FDA prescribing information.
- NIDDK overview of prescription weight loss medications.
- FDA information on semaglutide medications.
- WHO obesity and overweight fact sheet.
- CDC adult obesity facts and statistics.
Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical trial results represent averages and individual outcomes will vary. Always consult a qualified healthcare provider before starting any medication. Trimi offers semaglutide treatment — readers should be aware of our perspective.